1. Mortality risk with dual antiplatelet therapy?
Robert W Yeh, Sammy Elmariah, Gheorghe Doros, Dean J Kereiakes, Laura Mauri 
The Lancet 
Volume 386, Issue 10003, Pages (October 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure
Extended duration dual antiplatelet therapy and all-cause mortality
Updated comprehensive meta-analysis of trials assessing extended duration dual antiplatelet therapy (DAPT) in cardiovascular and cerebrovascular disease, showing no significant association between extended therapy and all-cause mortality. Data are n (events). *The six randomised clinical trials excluded by Palmerini and colleagues' study.2
The Lancet  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions